Geng Jingshu

Geng Jingshu

Auto-generated profile, based on publicly available information

Geng Jingshu

Department of Pathology

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SXSun Xian
Sun Xian
LJLang Jilu
Lang Jilu
TZTian Zhennan
Tian Zhennan
ZYZhou Yang
Zhou Yang
HYHu Yang
Hu Yang
SFSongbin Fu
Songbin Fu
To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found that the variant genotypes of 6007C > T polymorphisms significantly associated with the chemotherapy response. The 6007CC genotype carriers had a higher chance to be responder to chemotherapy (adjusted odd ratio = 2.77; 95% CI: 1.83–4.18; adjusted < 0.001). The 6007C > T polymorphisms and BMP-4 expression also affect the prognosis of NSCLC. Patients with high BMP-4 expression had a significantly higher chance to be resistant to chemotherapy than those with low BMP-4 expression (OR = 2.81; 95% CI: 1.23–6.44;P=0.01). The hazard ratio (HR) for 6007TT was 2.37 times higher than 6007CC (P=0.003). In summary, the 6007C > T polymorphism of BMP-4 gene and BMP-4 tissue expression may be used as potential predictor for the chemotherapy response and prognosis of advanced NSCLC.

16 August 2013
Verified
Journal Article
Closed access
HXHong Xuan
Hong Xuan
GJGeng Jingshu
Geng Jingshu
FYfang yang
fang yang
LNLi Na
Li Na
SXSheng Xiaolin
Sheng Xiaolin
CGChen Gongyan
Chen Gongyan